Search

Your search keyword '"Vaccinia virus enzymology"' showing total 638 results

Search Constraints

Start Over You searched for: Descriptor "Vaccinia virus enzymology" Remove constraint Descriptor: "Vaccinia virus enzymology"
638 results on '"Vaccinia virus enzymology"'

Search Results

1. Systematic genetic characterization of the human PKR kinase domain highlights its functional malleability to escape a poxvirus substrate mimic.

2. Structure and flexibility of the DNA polymerase holoenzyme of vaccinia virus.

3. Versatile strategy using vaccinia virus-capping enzyme to synthesize functional 5' cap-modified mRNAs.

4. Dysregulation of Cellular VRK1, BAF, and Innate Immune Signaling by the Vaccinia Virus B12 Pseudokinase.

5. Selection of Primer-Template Sequences That Bind with Enhanced Affinity to Vaccinia Virus E9 DNA Polymerase.

6. The SARS-CoV-2 RNA polymerase is a viral RNA capping enzyme.

7. A New Class of Uracil-DNA Glycosylase Inhibitors Active against Human and Vaccinia Virus Enzyme.

8. Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.

9. Solution Structure of the C-terminal Domain of A20, the Missing Brick for the Characterization of the Interface between Vaccinia Virus DNA Polymerase and its Processivity Factor.

10. Improving Immunoassay Performance with Cleavable Blocking of Microarrays.

11. The Vaccinia Virus B12 Pseudokinase Represses Viral Replication via Interaction with the Cellular Kinase VRK1 and Activation of the Antiviral Effector BAF.

12. Functional and computational identification of a rescue mutation near the active site of an mRNA methyltransferase.

13. Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines.

14. Antiviral activity of Apigenin against buffalopox: Novel mechanistic insights and drug-resistance considerations.

15. Monitoring of phosphorylation using immobilized kinases by on-line enzyme bioreactors hyphenated with High-Resolution Mass Spectrometry.

16. Expression and Purification of Vaccinia Virus DNA Topoisomerase IB Produced in the Silkworm-Baculovirus Expression System.

17. Viral and metazoan poxins are cGAMP-specific nucleases that restrict cGAS-STING signalling.

18. The vaccinia virus DNA polymerase structure provides insights into the mode of processivity factor binding.

19. Multisubunit DNA-Dependent RNA Polymerases from Vaccinia Virus and Other Nucleocytoplasmic Large-DNA Viruses: Impressions from the Age of Structure.

20. Deletion of the Vaccinia Virus B1 Kinase Reveals Essential Functions of This Enzyme Complemented Partly by the Homologous Cellular Kinase VRK2.

21. Characterization of DNA Binding by the Isolated N-Terminal Domain of Vaccinia Virus DNA Topoisomerase IB.

22. Trans-kingdom mimicry underlies ribosome customization by a poxvirus kinase.

23. The vaccinia virus DNA polymerase and its processivity factor.

24. The Vaccinia Virus H3 Envelope Protein, a Major Target of Neutralizing Antibodies, Exhibits a Glycosyltransferase Fold and Binds UDP-Glucose.

25. Crystal Structure of the Vaccinia Virus Uracil-DNA Glycosylase in Complex with DNA.

26. Doxycycline Inducible Melanogenic Vaccinia Virus as Theranostic Anti-Cancer Agent.

27. Binding of undamaged double stranded DNA to vaccinia virus uracil-DNA Glycosylase.

28. ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.

29. Poxvirus decapping enzymes enhance virulence by preventing the accumulation of dsRNA and the induction of innate antiviral responses.

30. Caps off to poxviruses.

31. The poxvirus encoded ubiquitin ligase, p28, is regulated by proteasomal degradation and autoubiquitination.

32. SMAC-armed vaccinia virus induces both apoptosis and necroptosis and synergizes the efficiency of vinblastine in HCC.

33. Nanoblinker: Brownian motion powered bio-nanomachine for FRET detection of phagocytic phase of apoptosis.

34. RE12 derivatives displaying Vaccinia H1-related phosphatase (VHR) inhibition in the presence of detergent and their anti-proliferative activity against HeLa cells.

35. Crystal structure of the vaccinia virus DNA polymerase holoenzyme subunit D4 in complex with the A20 N-terminal domain.

36. Crystal structure of vaccinia virus mRNA capping enzyme provides insights into the mechanism and evolution of the capping apparatus.

37. The D10 decapping enzyme of vaccinia virus contributes to decay of cellular and viral mRNAs and to virulence in mice.

38. Selective transport of cationized fluorescent topoisomerase into nuclei of live cells for DNA damage studies.

39. Structure of the uracil complex of Vaccinia virus uracil DNA glycosylase.

40. Vaccinia virus entry is followed by core activation and proteasome-mediated release of the immunomodulatory effector VH1 from lateral bodies.

41. Domain-level rocking motion within a polymerase that translocates on single-stranded nucleic acid.

42. Crystallization and preliminary X-ray diffraction analysis of three recombinant mutants of Vaccinia virus uracil DNA glycosylase.

43. Chemical mutagenesis of vaccinia DNA topoisomerase lysine 167 provides insights to the catalysis of DNA transesterification.

44. Atomic structure of dual-specificity phosphatase 26, a novel p53 phosphatase.

45. Protein kinase C overexpression does not enhance immune-stimulatory surface markers of vaccinia-infected dendritic cells and DC cell lines.

46. Thymidylate kinase: an old topic brings new perspectives.

47. A selective Seoul-Fluor-based bioprobe, SfBP, for vaccinia H1-related phosphatase--a dual-specific protein tyrosine phosphatase.

48. Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.

49. Molecular genetic and biochemical characterization of the vaccinia virus I3 protein, the replicative single-stranded DNA binding protein.

50. Unwinding initiation by the viral RNA helicase NPH-II.

Catalog

Books, media, physical & digital resources